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ABSTRAK
Tujuan: untuk mengembangkan tes diagnostik non invasif untuk NASH. Metode: penelitian ini menggunakan 
desain potong lintang dengan pengambilan sampel secara konsekutif. Kriteria diagnosis NAFLD berdasarkan 
biopsi hati. Variabel klinis yang dianalisis terdiri atas sindrom metabolik, AST, ALT, adiponektin, TNF-a, insulin, 
HOMA-IR indeks dan biopsi hati. Pasien dibagi menjadi 2 kelompok berdasarkan biopsi hati yaitu non NASH, 
skor NAFLD <3 dan NASH, skor NAFLD ≥4) Analisis statistik dilakukan menggunakan tes Student-t-, Mann 
Whitney U, chi-square, kurva ROC, dan sensitivitas, spesifisitas. Hasil: dari 50 pasien NAFLD (30 pria, 20 
wanita) 12 orang menderita diabetes tipe 2 (24%), 36 orang memiliki sindroma metabolik (72%) dan 2 orang 
tidak memenuhi kriteria sindroma metabolik (4%). Biopsi hati pasien menunjukkan 21 (42%) non NASH dan 29 
(58%) NASH. Terdapat perbedaan yang bermakna secara statistik antara dua kelompok AST, ALT, adiponektin 
dan TNF a. Kombinasi AST ≥25 U/L dan TNF-a >3,28 pg/cc mempunyai akurasi diagnostik yang baik untuk 
diagnosis NASH (Akurasi 82%, Sensitivitas 76%, Spesifisitas 90%, PPV 92%, dan NPV 73%. Kesimpulan: 
kombinasi AST dan kadar plasma TNF-a menunjukkan akurasi yang baik untuk mendeteksi NASH pada pasien 
NAFLD. Tes ini dapat digunakan sebagai metode non-invasif untuk mendiagnosis NASH.
Kata kunci: AST, TNF-a, tes diagnostik, NASH.
ABSTRACT
Aim: to develop a non-invasive diagnostic test for non-alcoholic steatohepatitis NASH. Methods: this is a 
cross-sectional study on non-alcoholic fatty liver disease (NAFLD) subjects. Sample was taken by consecutive 
sampling method. Diagnostic criteria of NAFLD were confirmed by liver biopsy. Clinical variables include 
metabolic syndrome, aspartate aminotransferase (AST), alanine aminotransferase (ALT), adiponectine, TNF-a, 
insulin, homeostatic model assessment insulin resistance (HOMA-IR) index and liver biopsy. Patients were 
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divided into two groups based on their liver biopsy, group 1: Non-NASH (NAFLD activity score <3) and group 
2: NASH (NAFLD activity score of >4). Statistical analyses were performed using Student’s t-test, Mann Whitney 
U, chi-square, the ROC curve, sensitivity and specificity test. Results: fifty NAFLD patients were recruited, 30 
males and 20 females. Among these patients, 12 (24%) had type 2 diabetes, 36 (72%) had metabolic syndrome, 
the remaining 2 (4%) did not fulfilled metabolic syndrome. Liver biopsy confirmed 21 (42%) non- NASH and 
29 (58%) NASH respectively. Level of AST and ALT, plasma level of adiponectine and TNF-a were statistically 
different between two groups. The AST level (>25 U/L) in combination with TNF-a (>3.28 pg/cc) demonstrated 
a good diagnostic accuracy for NASH (Accuracy 82%, Sensitivity 76%, Specificity 90%, PPV 92%, and NPV 
73%). Conclusion: the combined diagnostic tests of AST and TNF-a plasma levels demonstrated a good accuracy 
for the detection of NASH among NAFLD patients. This combination test can be used as a noninvasive method 
to diagnose NASH.
Key words: AST, TNF-a, diagnostic test, NASH.
INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) 
has become an emerging problem worldwide as 
a result of increased incidence of obesity. The 
severity spectrum of liver damage is ranging from 
simple macrovesicular steatosis to steatohepatitis 
(NASH), cirrhosis or liver carcinoma.1 In the 
general population, the estimated prevalence 
ranges between 20 and 30% in the Caucasian 
and 30% in Indonesian.2,3
Majori ty of  NAFLD patients  were 
asymptomatic,  therefore,  case f inding 
usually begins after detection of abnormal 
liver enzymes on routine evaluation.4 Serum 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) quite often shows mild 
to moderate elevation, while the correlation 
with gammaglutaril-transferase (GGT) remains 
uncertain. Therefore, there is no overall 
correlation between the degree of liver enzyme 
elevation and the level of damage observed on 
histopathological analysis.1,4
Non-alcoholic steatohepatitis is the severe 
histological form of NAFLD. It is emerging 
as the most common clinically important form 
of liver disease in obese patients, diabetes and 
metabolic syndrome.5-9 Liver biopsy is invasive 
and expensive, however, it is the gold standard 
for the diagnosis of NASH to differentiate 
simple bland steatosis. Liver biopsy has several 
limitations and not easily performed, since, it is 
an invasive method with potentially important 
complications happening with a mortality and 
morbidity rate of 0.03 and 3% respectively. 
Moreover, a percutaneous liver biopsy obtain 
only a very small piece of the liver (~1/50,000 
of whole size of the liver), leading to major 
sampling variability (25%-40%) and bias of 
inter-observer as high as 20%.10
Ultrasound (US), computerized tomography 
(CT), magnetic resonance imaging (MRI), and 
H magnetic resonance spectroscopy (H MRS) 
are noninvasive methods. However, they do 
not provide reliable quantitative information.11 
Because of these limitations, it is important 
to develop new methods to asses NAFLD, 
particularly the presence or absence of NASH 
and the severity of any complicating fibrosis or 
cirrhosis. To achieve this aim, the tests should 
be non-invasive, accurate, reproducible and 
affordable.12 Studies to determine non-invasive 
diagnostic tests of NASH in NAFLD patients 
in Indonesia were rarely conducted, therefore 
producing clinical laboratory tool that capable for 
identifying individual with most risk for NASH 
in NAFLD patients is important. This study 
was aimed at producing a clinical laboratory 
tool capable of identifying individual with 
most risk for NASH in NAFLD patients. In 
addition, this tool will predict NASH without 
the risks associated with hepatic biopsy and 
clinically important to prognosis and therapeutic 
intervention.
METHODS
This cross-sectional study was performed 
on NAFLD patients at the outpatient clinic of 
Dr. Kariadi Hospital, Semarang between August 
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2009 and July 2011. Recruitment was conducted 
using consecutive sampling method. Inclusion 
criteria for this study were patients with one 
or more symptoms of metabolic syndrome 
and feature of fatty liver by ultrasound. These 
patients should be confirmed for diagnostic 
of NAFLD and the severity of liver damage 
using histopathology biopsy without any other 
evidence of liver injury due to alcoholism or 
viral hepatitis. Patients with alcohol consumption 
more than 20 g per day or having regular intake 
of drugs which were known to produce steatosis 
or any other circumstance with associated liver 
disease were excluded. This study was approved 
by the human research ethics committee of The 
Faculty of Medicine Diponegoro University–Dr 
Kariadi Hospital Semarang and informed consent 
was obtained from each patient.
The following data were evaluated: gender, 
age, body mass index (BMI), waist circumference, 
presence of hypertension and diabetes mellitus, 
high density lipoprotein (HDL), fasting 
glucose (FG), triglycerides, homeostatic model 
assessment of insuline resistance (HOMA-
IR) index, aspartate aminotransferase (AST), 
alanin aminotransferase (ALT), plasma levels 
of adiponectine and TNF-a from the 50 patients 
recruited. Plasma levels of Insuline, adiponectine 
and TNF-a were measured using ELISA method. 
The diagnosis of metabolic syndrome followed 
the criteria established by the International 
Diabetes Federation (IDF) 2005.13
NAFLD was  d iagnosed  based  on 
ultrasound by 2 radiologists (Kappa=0.8). 
The ultrasonography criteria that were used to 
diagnose and severity of fatty liver was described 
as previous study by Sherif Saadeh, et al.14
Liver biopsy was performed in all 50 
patients with ultrasound-guided using a 
16-gauge Menghini type needle (Hepafix® B. 
Braun Melsungen AG, Germany) under local 
anesthesia.15 All liver biopsies were reviewed by 
two experienced pathologists (Kappa=0.87) who 
were blinded to the patient data. Diagnosis of 
NASH was based on Histological Scoring System 
for Non Alcoholic Fatty Liver Disease Score and 
Fibrosis staging by NASH clinical research 
network (CRN) scoring system (NAFLD activity 
score=NAS). Based on the scoring system, the 
value of NAS <2 = Simple Fatty, NAS 3-4 = 
Possible NAS and NAS ≥5 = NASH.16
Patients were classified by modified NAS in 
two groups: Non-NASH group (patients without 
NAFLD if NAS <3 and NASH group if NAS ≥4. 
Demographic, laboratory and imaging data were 
compared between both groups).
Statistical analyses used were student T-test, 
Mann Whitney U test, chi-square test and ROC 
curve analysis. To evaluate the sensitivity and 
specificity of cut off levels, computer software 
SPSS for Windows PC version 21 (SPSS Inc, 
Chicago, IL) and a significant level of 5% were 
used.
RESULTS
We evaluated 50 patients with NAFLD, 30 
(60%) male, with mean (SD) of 45.5 (10.4) years 
of age and median of BMI of 29.5 kg/m (22.0-
47.5), mean (SD) of waist circumference 100.2 
cm (10.8), Metabolic syndrome was present in 
36 patients (72%) and type 2 DM in 12 subjects 
(8 male). The chief complaints of these patients 
consist of 10% asymptomatic, 30% fatigue, 60% 
abdominal discomfort. Clinical manifestation 
of the patients were obesity/BMI>25 kg/m2 
(82%), hypertriglyceridemia (78%), fasting 
hyperglycemia in 56% patients and level of ALT 
(72%) and AST (62%) patients within normal 
range, diabetes (24%) and hypertension in 50% 
patients. (Table 1)
Female presented higher BMI 30.2 (24-47) 
kg/m than male 28.5 (22-40) p=0.03 Mann-
Whitney U test), and it similar age (males 42.5 y 
(29-74); female: 49.0 y (23-61), p=0.27, Mann-
Whitney U test). The proportion of cases with 
metabolic syndrome was also similar (males 
24/30 cases; women 12/20 cases, p=0.12, chi-
square test). Metabolic syndrome occurrence was 
similar in the NASH group (22/29 cases) when 
compared to Non NASH group (14/21; p=0.47, 
chi-square test).
Based on the results of liver biopsy; 21 
(42%) were non NASH and 29 (58%) patients 
were NASH and non fibrosis (62%). (Table 2) 
The degree of fatty liver (FL) by ultrasound 
were as follow; 29 patients (58%) FL grade I, 
13 (26%) FL grade II, and 8 patients FL grade 
III. Abdominal US with degree/grade II/III 
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associated with presence of NASH p=0.027) 
sensitivity and specificity of 52.2% and 76.2%, 
respectively to identify NASH.
There were no statistically differences in the 
variables of age, BMI, waist circumference, HDL 
cholesterol, triglyceride, fasting blood sugar, 
insuline and HOMA-IR between two groups. 
There were statistically differences in variables 
of AST, ALT, adiponectine, and plasma levels of 
TNF-a between the two groups. (Table 1)
TNF-a and AST cut-off values were 
determine separately from smallest distance 
value that computed from the value of sensitivity 
and specivity from ROC curve analysis. Using 
receiver operating characteristic (ROC) analysis, 
we established the following best cut –off levels 
(equal or above being indicative of NASH: ALT 
>53.5 IU/L, AST >25 IU/L, TNF-a >3.28 pg/
ml, adiponectine <2174 ng/ml. (Table 3, Figure 
1). Each test alone produced low accuracy; 
therefore, we decided to evaluate combination 
between two markers to obtain the best accuracy. 
ROC curve of combination TNF-a and AST 
were generated from predictive value of TNF-a 
and AST for NASH prediction from logistic 
regression analysis output. Combination of serum 
AST (>25U/L) and plasma levels of TNF-a (3.28 
pg/cc) has a moderate accuracy as a non-invasive 
diagnostic test for detection of NASH. (Accuracy 
82%, Sensitivity 76%, Specificity 90%, PPV 92%, 
and NPV 73%). (Figure 2)
Table 1. Clinical and laboratory characteristics of the groups
Variables
Non-NASH
Mean (SD),  
Median (Range)
NASH
Mean (SD),  
Median (Range)
p
Ages (years) 44.7 (11.4) 46.3 (10) 0.50
BMI (kg/m2) 30.1 (23-38) 29.0 (22-47) 0.79
Waist Circumference (cm) 100.8 (8.5) 100.1(12.3) 0.24
Cholesterol total (gr/dl) 205.2 (50) 196 (32.3) 0.11
Triglyceride (gr/dl) 202 (54-643) 205 (48-467) 0.24
Fasting glucose (gr/dl) 101 (87-202) 102 (68-208) 0.48
AST (IU/L) 25 (17-77) 40 (10-120) 0.019*
ALT (IU/l) 50 (14-177) 60 (19-264) 0.045*
Adiponectine (ng/ml) 4222 (493-9766) 2116 (679-4500) 0.005*
TNF-a (pg/ml) 3.35 (1.8-87) 11.55(1.6-332) 0.001*
Insuline (mIU/ml) 10.02 (1.8-87) 14.8 (2.0-117) 0.163
Homa IR-index 3.3 (0.6-20)  4.5 (0.4-29) 0.258
*P<0.05
Table 2. Distribution of NAFLD activity score according to 
the liver biopsy; NASH or Non-NASH
NASH non-NASH
Fatty Liver (NAS <2) 21 cases
Possible NASH (NAS 3-4) 13 cases
NASH (NAS ≥5) 16 cases
Fibrosis positive 8 cases 5 cases
Fibrosis negative 21 case 16 cases
Table 3. Cut-off and ROC curve analysis of each marker for NASH
Test Cut-Off AUC (95% CI) p Sensitivity Specificity
AST (IU/L) 25 IU/L 66.7% (51.6-81.9) 0.019 79 52
ALT (IU/L) 53.5 IU/L 69.6% (54.7-84.0) 0.045 79 62
TNF-a (pg/ml) 3.28 pg/ml 77.8% (64.9-90) 0.001 93 48
Adiponectine (ng/ml) 2174 g/ml 73.6% (58.4- 88.8) 0.005 66 71
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DISCUSSION
NAFLD is often not diagnosed properly 
in clinical practice because it is usually 
asymptomatic. Previous study showed that the 
majority of patient’s complaints are discomfort 
in the abdomen and fatigue which is similar with 
our study.17 These symptoms are not specific to 
NAFLD but vague discomfort over the liver 
with hepatomegaly is common among patients 
with NAFLD in hospital setting. However, in the 
general population it is most often asymptomatic. 
This study demonstrated that 82% of patients 
with obesity (BMI>25 kg/m2) and 72% with 
metabolic syndrome. Some studies showed that 
obesity is a metabolic illness closely associated 
with both steatosis and NASH. In addition, the 
severity of the hepatic illnes is related to the 
increase of BMI.18,19 
Another study found difference with 
this statement, that BMI did not differ 
between groups with and without NASH in 
morbidly obese patients, and that insuline 
resistance, hypertension, and elevated ALT 
were independently predicted the presence of 
NASH.20,21 Our study showed that BMI and 
waist circumference, metabolic syndrome, ages, 
cholesterol total, triglyceride, fasting glucose, 
insulin resistance did not differ between groups 
with and without NASH. 
The major abnormalities of serum liver are 
elevations of ALT and AST level. The majority of 
elevations are mild (<5x the upper normal limit), 
and exist in all degrees of NAFLD. However, 
there is no correlation between the degree of 
liver enzyme elevation and the level of damage 
observed in histopathological analysis. This 
study showed that the level of ALT and AST 
in majority of NAFLD patients were in normal 
laboratory range. However, there was a significant 
difference in group of NASH and without NASH 
(Table 1). Alanine aminotransferase (ALT) has 
been used as a substitute indicator for liver 
lesion. Some studies recommended that ALT 
is not an ideal biomarker for the diagnosis of 
NAFLD or distinguish steatosis from NASH. 
In a cross-sectional population study, based 
on hepatic triglyceride content by magnetic 
resonance spectroscopy for diagnose hepatic 
steatosis, nearly one-third (31%) of the patients 
Figure 1. ROC analysis result of AST, ALT, TNF-a and 
adiponectin to identify presentation of NASH. TNF-a and 








Figure 2. ROC curve of combination AST and TNF-a for 
NASH prediction (n=50). Area under the curve was 0,841 
(95% CI= 0,73 to 0,95) p<0,001
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had hepatic steatosis. The majority of the patients 
with steatosis (79%) had normal serum ALT 
values. In another study, 58 out of 80 (72.5%) 
subjects who had ALT within normal value had 
varying degree of NASH during underwent 
surgery irrelevant to liver diseases. Twenty six 
patients had fibrosis and 8 had silent cirrhosis. 
The third study reported that the whole histologic 
continuum of NAFLD could be observed in the 
individuals within normal limit of ALT. The 
histological continuum of NAFLD in subjects 
with NAFLD and ALT within normal limit 
was not significantly different from those with 
NAFLD and elevated ALT. A low normal ALT 
value, therefore, does not guarantee to rule out 
of NASH and advanced fibrosis.22
Metabolic syndrome and insuline resistance 
in this study were not significantly different 
between NASH and non-NASH patients. This 
is probably due to proportion of samples as well 
as no significant difference in the frequency of 
central obesity in both groups. Various studies 
have shown that the basic components of the 
insulin resistance/metabolic syndrome are the 
presence of central obesity.
Adiponectine is plentiful adipocyte-
derived hormone with well recognized anti-
inflammatory and insulin sensitizing activity. 
Hypoadiponectinemia along with insulin 
resistance proved to be an independent risk 
factors for the metabolic syndrome.23 The 
importance of adiponectine in protecting 
obesity-related NAFLD has been gradually more 
established. Even though the advances made in 
current years, the comprehensive underlying 
mechanism of hepato-protective functions 
remains largely undetermined.22 Adiponectine 
usually predicts degree of steatosis and the 
severity of NAFLD; nevertheless, to what level 
this is a direct consequence or linked to the 
existence of more severe insulin resistance or 
obesity remains to be handled. Our study showed 
that plasma level adiponectine is significantly 
higher in non-NASH group compared to NASH 
group. Rinaldi (2009) also reported similar 
results with our study.17,24
Several data support the pathophysiological 
role of tumor necrosis factor (TNF) in non-
alcoholic fatty liver disease (NAFLD).25,26 Obese 
and NASH patients have high plasma level 
of TNF because TNF gene expression is also 
increased in adipose and liver tissue of obese 
patients. NASH patients with hepatic fibrosis 
have higher TNF mRNA expression. Prevalence 
of TNF polymorphism was increased in NAFLD 
patients. NASH have similar liver histology 
with alcoholic steatohepatitis (ASH), a disease 
in which TNF is recognized to be an essential 
pathophysiological roles.25 Our study found that 
plasma level of TNF-a is more higher in NASH 
compared to non-NASH group.
TNF-α plays a significant role in insulin 
resistance,the main characteristic of metabolic 
syndrome through inhibition of tyrosine kinase 
activity of the insuline receptor. Abiru et 
al. (2006) reported that NASH patients had 
significantly higher serum TNF-α and its soluble 
receptor (sTNFR1) than those with simple fatty 
liver, even though they did not give a cut-off 
value of the cytokine for clinical use. Current 
study reported that NASH patients had higher 
levels of TNF-α messenger ribonucleic acid 
(mRNA) than healthy controls. TNF-α mRNA 
cut-off value of 100 ng/mL for prediction 
of NASH [area under receiver operating 
characteristic curves (AUROC) 0.685, sensitivity 
66.7%, specificity 74.1%].22
In clinical practice, the ideal biomarkers 
or panels of biomarkers are urgently needed 
which are cheaper, reliable, and reproducible 
for patients with NASH. It is needed to be 
able to assist in diagnosis, providing risk 
information, and monitoring disease progression 
and treatment response. Our study suggests that 
serum AST >25 IU/l and plasma level of TNF-a 
of 3.28 pg/ml had the best diagnostic value for 
the presence of NASH. To our knowledge this is 
the first study using combination of serum AST 
plus TNF-a plasma level for diagnosis NASH 
in NAFLD patients.
Various non-invasive diagnostic tests for 
NASH that have been studied include contrast 
enhanced ultrasound, NASH test and CK-18. 
Contrast enhanced ultrasound demonstrated 
AUROC of 100% for diagnosis of NASH. 
NASH test has Specificity, Sensitivity, PPV and 
NPV of 94%, 33%, 66% and 81% respectively 
for diagnosis of NASH. CK -18 was AUROC, 
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sensitivity and specificity for NASH of 0.82, 0.78 
and 0.87 respectively.19 Recent study concluded 
that serum fragmented CK-18 levels can be used 
to distinguish NASH with NAFL.18,27
Our study proves that the combination of 
level AST serum and TNF-a plasma can be used 
in clinical practice to diagnose the presence of 
NASH. At least it can be utilized in predicting 
the presence of NASH.
It should be considered that this study 
involved a small number (single center) of 
patients. Therefore, larger or multicenter studies 
are required to obtain more consistent results 
in order to be applied in clinical practice. 
Furthermore, another limitation is that healthy 
controls were not included in this study. As a 
consequence, we cannot observe the spectrum 
of abnormalities from normal to some extent of 
conditions, so that the implementation of this 
study is of limited only in patients with NAFLD, 
does not include a healthy population/without 
risk factors.
CONCLUSION
The combination between AST serum and 
plasma levels of TNF-a tests showed a moderate 
accuracy for the detection of NASH among 
patients with NAFLD. This combination can be 
utilized as a screening tool for NASH in NAFLD 
patients, and can be alternative of liver biopsy 
for diagnosis of NASH. Further studies are still 
needed using large number of samples or using 
multicenter study in effort to examine this tool 
as a non- invasive diagnostic test for NASH in 
clinical practice.
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